According to Arizton’s latest research report, the Alzheimer’s disease therapeutics market will grow at a CAGR of 12.19% during 2022-2028.
To Know More, Download the Free Sample Report: https://www.arizton.com/request-sample/3634
Market Overview:
Alzheimer’s disease is the most common cause of dementia among individuals aged 60 and above. It accounts for approximately 75% of the total cases of dementia worldwide. The incidence rate of Alzheimer’s appears to be declining. This decline has been attributed to improvements in Alzheimer’s risk factors, such as hypertension. However, even with this potentially low incidence rate, the number of individuals suffering from Alzheimer’s is expected to continue growing because of an increase in adults aged 65 and above. According to estimates, the total number of individuals with Alzheimer’s or other types of dementia in the US and other high-income Western countries is expected to continue to increase dramatically due to the geriatric population. In 2020, an estimated 5.8 million Americans aged 65 had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060.
Alzheimer’s Disease Therapeutics Market Report Scope
| Report Scope | Details |
| Market Size (2028) | USD 7.16 Billion |
| Market Size (2022) | USD 3.59 Billion |
| CAGR (2022-2028) | 12.19% |
| Historic Year | 2019-2021 |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segmentation | Drug Class, Gender Type, Age Group, Severity Type, and Geography |
| Countries Covered | United States, France, Germany, Italy, the UK, Spain, China, and Japan |
| Market Dynamics |
|
Looking for More Information? Download the Free Sample Report: https://www.arizton.com/request-sample/3634
Key Milestones in The Alzheimer’s Disease Therapeutics Market:
- In April 2022, Biogen Announced that the European Medicines Agency (EMA) had withdrawn its Marketing Authorization Application (MAA) for aducanumab to treat the early stages of Alzheimer’s disease due to a lack of sufficient data.
- In March 2022, Corium, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Adlarity (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of Alzheimer’s Disease.
- In June 2021, Biogen Announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Aduhelm (aducanumab-avwa) to treat early Alzheimer’s disease. The approval is based on two Phase 3 clinical trials—EMERGE (Study 1) and ENGAGE (Study 2)—in patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) with confirmed presence of amyloid pathology.
Report Coverage
- Detailed overview of Alzheimer’s Disease, including disease definition, classification, diagnosis, and treatment pattern.
- Overview of the global trends of Alzheimer’s Disease in the eight major markets (8MM)
- The historical, current, and projected patient pool of Alzheimer’s Disease in the eight major markets (8MM) for 2019 – 2028.
- Gender type, Drug Class, Age group, Severity type, and Geography type segmentations of Alzheimer’s Disease in the eight major markets (8MM).
- The historical, current, and projected market size of Alzheimer’s Disease in the eight major markets (8MM) for the 2019 – 2028 period.
- In-depth market segment analysis, including products, treatment, and competitor analysis.
- Market share of the players, company profiles, product specifications, and competitive landscape.
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints.
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alzheimer’s Disease across the complete product development cycle, including all clinical and non-clinical stages.
- Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for Alzheimer’s Disease across all clinical stages.
- Coverage of dormant and discontinued pipeline projects and the reasons across Alzheimer’s Disease.
- Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the Alzheimer’s Disease space.
Market Segmentation
Drug Class: ACE Inhibitors, NMDA Inhibitors, and Other Drug class
Gender Type: Men and Women
Age Group: 65-74 years, 75-84 years, and 85 years & Above
Severity Type: Mild, Moderate, and Severe
Geography: North America (United States), APAC (China, Japan), and Europe (France, Germany, Italy, Spain, and the UK)
Customization Available
Our team is always ready to answer your questions and concerns, guide you through the purchasing process, and dive into the research report. To learn more about the medical tent market, request an Analyst Brief from Arizton Advisory & Intelligence; our sales team will assist you in making an informed market decision to achieve market growth. We also provide customization solutions based on your business requirements and assistance with your questions and future goals. Our researchers will prioritize your interests and investigate all possible avenues to increase your business profits.
To Get the Benefit of Our Free Report Customization Service, Send Your Enquiry Here – https://www.arizton.com/customize-report/3478
Why Arizton Research Reports?
100% Customer Satisfaction
24×7 availability – we are always there when you need us.
200+ Fortune 500 Companies trust Arizton’s report.
80% of our reports are exclusive and first in the industry.
100% more data and analysis.
1000+ reports published to date.
Arizton’s Expertise in the Healthcare Industry
Arizton offers syndicate and custom market intelligence & competitive intelligence solutions across MedTech, pharmaceuticals, and life sciences & biotechnology markets within the healthcare industry. Arizton’s healthcare vertical provides unbiased research and evidence-based analysis to support business decisions and comprehensive end-to-end solutions to its customers, covering all dimensions of the healthcare value chain. We track various devices (equipment, implants, and hospital supplies) and drugs (patented, generic, & OTC) across North America, Europe, APAC, Latin America, and the Middle East & Africa regions. The healthcare reports provide historic and forecast data for 20+ key countries worldwide. We track product approvals/launches, M&A activities, and collaboration/partnership activities among pharma/biotech, medical device, and life sciences companies. Our pharmaceutical portfolio tracks 15+ therapy areas with a major focus on immunology, oncology, rare & genetic diseases, dermatology, and metabolic diseases. Our medical devices and life sciences portfolio covers in-vitro diagnostics, healthcare IT, patient monitoring, cardiovascular devices, medical imaging, personal protective equipment, clinical laboratory services, and CMO/CDMO services.
Explore more healthcare reports: https://www.arizton.com/market-reports/category/healthcare-lifesciences
Check More Top-Selling Research Reports:
Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027
https://www.arizton.com/market-reports/hepatocellular-carcinoma-treatment-market
Atopic Dermatitis Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027
https://www.arizton.com/market-reports/atopic-dermatitis-treatment-market
Psoriatic Arthritis Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027
https://www.arizton.com/market-reports/psoriatic-arthritis-treatment-market
Crohn’s Disease Therapeutics Market Forecast – Epidemiology & Pipeline Analysis
https://www.arizton.com/market-reports/crohns-disease-therapeutics-market
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Contact Us:
Call: +1-312-235-2040
+1 302 469 0707
Mail: enquiry@arizton.com
Contact Us: https://www.arizton.com/contact-us
Blog: https://www.arizton.com/blog
Website: https://www.arizton.com/